Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor Combined With Olaparib in Recurrent/Refractory Extensive-stage SCLC
NCT05975944Phase 2Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Sep 2023
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of selinexor in small cell lung cancer (SCLC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Status: unknown.
02
Drugs
selinexor
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05975944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05975944.